Robbie Stephens Keeps 'Buy' on Amgen

Analyst Michael King says the FDA's rejection of its Plenaxis drug should have little long-term impact for the drugmaker

Robertson Stephens reiterates its buy rating and the $77 one-year target on Amgen (AMGN ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.